# Mitral Transcatheter Edge-to-Edge Repair In-Hospital Outcomes and Mitral Valve Surgery Readmission Trends: National Readmission Database 2018-2020

**Authors:** Abdul Rahman Akkawi, Syed Zaid, Taha Hatab, Rody G. Bou Chaaya, Emmanuel Oundo, Nadeen Faza, Stephen H. Little, Marvin D. Atkins, Michael J. Reardon, William A. Zoghbi, Neal S. Kleiman, Sachin S. Goel

PMC · DOI: 10.1016/j.shj.2024.100350 · Structural Heart · 2024-07-27

## TL;DR

This study analyzed in-hospital outcomes and readmission trends for patients who underwent mitral transcatheter edge-to-edge repair, finding a low readmission rate and a decline over time.

## Contribution

The study provides new insights into the effectiveness and safety of transcatheter edge-to-edge repair using a national database.

## Key findings

- Only 1.1% of patients required mitral valve surgery within 180 days after transcatheter repair.
- Readmission rates for surgery dropped significantly from 1.8% in 2018 to 0.8% in 2020.
- Younger age was an independent predictor of readmission for mitral valve surgery.

## Abstract

•Study design: Utilized the National Readmission Database from 2018-2020. The study included patients over 18 years of age who underwent transcatheter edge-to-edge repair and analyzed readmission for mitral valve (MV) surgery within 180 days.•Readmission rate: Only 1.1% of patients who underwent transcatheter edge-to-edge repair required MV surgery within 180 days.•Mortality and morbidity: In-hospital mortality after MV surgery was 9.7%, with a high incidence of acute kidney injury (51%) and bleeding events (15.7%) among readmitted patients.•Trend over time: The readmission rate for MV surgery significantly declined from 1.8% in 2018 to 0.8% in 2020.•Predictors of readmission: Younger age was identified as an independent predictor of readmission for MV surgery.

Study design: Utilized the National Readmission Database from 2018-2020. The study included patients over 18 years of age who underwent transcatheter edge-to-edge repair and analyzed readmission for mitral valve (MV) surgery within 180 days.

Readmission rate: Only 1.1% of patients who underwent transcatheter edge-to-edge repair required MV surgery within 180 days.

Mortality and morbidity: In-hospital mortality after MV surgery was 9.7%, with a high incidence of acute kidney injury (51%) and bleeding events (15.7%) among readmitted patients.

Trend over time: The readmission rate for MV surgery significantly declined from 1.8% in 2018 to 0.8% in 2020.

Predictors of readmission: Younger age was identified as an independent predictor of readmission for MV surgery.

## Linked entities

- **Diseases:** acute kidney injury (MONDO:0002492)

## Full-text entities

- **Diseases:** bleeding (MESH:D006470), acute kidney injury (MESH:D058186)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11925025/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11925025/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC11925025/full.md

---
Source: https://tomesphere.com/paper/PMC11925025